Mauro Bove - Regenerx Biopharm Independent Director
| RGRXDelisted Stock | USD 0.0009 0.0001 12.50% |
Director
Mr. Mauro Bove is Independent Director of the Company. He has more than 30 years of business and management experience within the pharmaceutical industry. Mr. Bove is currently serving as Senior Vice President of Business Development at Lee Pharmaceutical Holdings Inc, based in Hong Kong and is a consultant to emerging pharmaceutical companies in Asia. Previously, Mr. Bove led for more than 20 years the Corporationrationrate Business Development of SigmaTau Finanziaria S.p.A., formerly the holding company of SigmaTau Group, a leading international pharmaceutical company . Mr. Bove, who resigned this role with SigmaTau on March 31, 2014, has also held a number of senior positions in business, licensing and corporate development within SigmaTau Group. Mr. Bove obtained his law degree at the University of Parma, Italy, in 1980. In 1985, he attended the Academy of American and International Laws at the International and Comparative Law Center, Dallas, Texas. The Board believes that Mr. Boves extensive business and management experience within the pharmaceutical industry allows him to recognize and advise the Board with respect to recent industry developments. since 2004.
| Age | 62 |
| Tenure | 20 years |
| Phone | 301 208 9191 |
| Web | https://www.regenerx.com |
Regenerx Biopharm Management Efficiency
The company has return on total asset (ROA) of (0.8397) % which means that it has lost $0.8397 on every $100 spent on assets. This is way below average. Regenerx Biopharm's management efficiency ratios could be used to measure how well Regenerx Biopharm manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.14 M in liabilities. Regenerx Biopharm has a current ratio of 1.03, suggesting that it may have difficulties to pay its financial obligations when due. Debt can assist Regenerx Biopharm until it has trouble settling it off, either with new capital or with free cash flow. So, Regenerx Biopharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regenerx Biopharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regenerx to invest in growth at high rates of return. When we think about Regenerx Biopharm's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | DIRECTOR Age | ||
| David Barrett | Fortress Biotech Pref | 39 | |
| Jimmie Harvey | Fortress Biotech Pref | 62 | |
| Jay Lobell | Fortress Biotech Pref | 51 | |
| Kevin Lorenz | Fortress Biotech Pref | N/A | |
| Malcolm Hoenlein | Fortress Biotech Pref | 73 | |
| Todd Caven | Regen BioPharma | 52 | |
Management Performance
| Return On Asset | -0.84 |
Regenerx Biopharm Leadership Team
Elected by the shareholders, the Regenerx Biopharm's board of directors comprises two types of representatives: Regenerx Biopharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regenerx. The board's role is to monitor Regenerx Biopharm's management team and ensure that shareholders' interests are well served. Regenerx Biopharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regenerx Biopharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| J Finkelstein, CEO and President and Director | ||
| Nabila Turjman, Ex Affairs | ||
| Don Elsey, Independent Director | ||
| Allan Goldstein, Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board | ||
| Alessandro Noseda, Director | ||
| Joseph McNay, Independent Director | ||
| Raymond Elsey, Independent Director | ||
| Mauro Bove, Independent Director |
Regenerx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Regenerx Biopharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.84 | ||||
| Operating Margin | (19.03) % | ||||
| Current Valuation | 22.91 M | ||||
| Shares Outstanding | 143.55 M | ||||
| Shares Owned By Insiders | 45.99 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 19.19 K | ||||
| Price To Earning | 17.73 X | ||||
| Price To Sales | 261.81 X | ||||
| Revenue | 76.76 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regenerx Biopharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regenerx Biopharm's short interest history, or implied volatility extrapolated from Regenerx Biopharm options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |